Pharmacogenetics of warfarin: Development of a dosing algorithm for Brazilian patients (Clinical Pharmacology Therapeutics (2008) 84, (722-728) DOI: 10.1038/clpt.2008.166);Pharmacogenetics of warfarin: Development of a dosing algorithm for Brazilian patients

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 6, 2008, Pages 722-728

  Perini, J A ^a   Struchiner, C J ^b   Silva Assuncao E ^c   Santana, I S C ^a   Rangel, F ^c   Ojopi, E B ^d   Dias Neto, E ^d   Suarez Kurtz, G ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c INSTITUTO NACIONAL DE CARDIOLOGIA   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGOXIN; DILTIAZEM; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ISOSORBIDE; LOSARTAN; PENICILLIN G; PROPRANOLOL; SIMVASTATIN; SPIRONOLACTONE; VERAPAMIL; WARFARIN;

ADULT; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; BRAZIL; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; DOSE CALCULATION; DRUG INDICATION; DYSLIPIDEMIA; ETHNIC GROUP; FEMALE; GENE LINKAGE DISEQUILIBRIUM; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; RHEUMATIC FEVER; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; THROMBOEMBOLISM;

EID: 56549125038     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.11     Document Type: Erratum

References (38)

1. Levine, M.N., Raskob, G., Landefeld, S. & Kearon, C. Hemorrhagic complications of anticoagulant treatment. Chest 119 (suppl. 1),108S-121S (2001).
2. Wadelius, M. et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
3. Rieder, M.J. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
4. Lee, S.C. et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006).
5. Takahashi, H. et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
6. Schelleman, H. et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81, 742-747 (2007).
7. Michaud, V. et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 83, 740-748 (2007).
8. Oldenburg, J., Bevans, C.G., Fregin, A., Geisen, C., Müller-Reible, C. & Watzka, M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb. Haemost. 98, 570-578 (2007).
9. Yin, T. & Miyata, T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb. Res. 120, 1-10 (2007).
10. Momary, K.M., Shapiro, N.L., Viana, M.A., Nutescu, E.A., Helgason, C.M. & Cavallari, L.H. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8, 1535-1544 (2007).
11. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 2008); e-pub ahead of print 27 February 2008.
12. Limdi, N.A. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther. 83, 312-321 (2008).
13. Schwarz, U.I. et al. Genetic determinants of response to warfarin during initial anticoagulation. N. Engl. J. Med. 358, 999-1008 (2008).
14. Kaminsky, L.S. & Zhang, Z.Y. Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997).
15. Li, T., Chang, C.Y., Jin, D.Y., Lin, P.J., Khvorova, A. & Stafford, D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544 (2004).
16. Rost, S. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541 (2004).
17. Suarez-Kurtz, G. Pharmacogenetics in admixed populations. Trends Pharmacol. Sci. 26, 196-201 (2005).
18. Suarez-Kurtz, G. & Pena, S.D. Pharmacogenomics in the Americas: the impact of genetic admixture. Curr. Drug Targets 7, 1649-1658 (2006).
19. Suarez-Kurtz, G. & Pena, S.D.J. Pharmacogenetics in the Brazilian population. In: Pharmacogenomics in Admixed Populations (ed. Suarez-Kurtz, G.) 75-98 (Landes Bioscience, Austin, TX, 2007) 〈http://www.eurekah.com/ chapter/3157〉.
20. Vianna-Jorge, R., Perini, J.A., Rondinelli, E. & Suarez-Kurtz, G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 76, 18-26 (2004).
21. Lima, M.V., Ribeiro, G.S., Mesquita, E.T., Victer, P.R. & Vianna-Jorge, R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur. J. Clin. Pharmacol. 64, 9-15 (2008).
22. Sconce, E.A. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
23. Zhu, Y. et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639G>A) and CYP2C9 genotypes. Clin. Chem. 53, 1199-1205 (2007).
24. Carlquist, J.F. et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22, 191-197 (2006).
25. Aquilante, C.L. et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
26. Obayashi, K. et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169-178 (2006).
27. Caldwell, M.D. et al. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5, 8-16 (2007).
28. Gage, B.F., Eby, C., Milligan, P.E., Banet, G.A., Duncan, J.R. & McLeod, H.L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91, 87-94 (2004).
29. Yuan, H.Y. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14, 1745-1751 (2005).
30. Suarez-Kurtz, G., Vargens, D.D., Struchiner, C.J., Bastos-Rodrigues, L. & Pena, S.D. Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet. Genomics 17, 765-771 (2007).
31. Suarez-Kurtz, G., Perini, J.A., Bastos-Rodrigues, L., Pena, S.D. & Struchiner, C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 8, 1299-1306 (2007).
32. Estrela, R.C. et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 9, 267-276 (2008).
33. Suarez-Kurtz, G. The implications of population admixture in race-based drug prescription. Clin. Pharmacol. Ther. 83, 399-400 (2008).
34. Suarez-Kurtz, G. Ethnic differences in drug therapy: a pharmacogenomics perspective. Exp. Rev. Clin. Pharmacol. 1, 337-339 (2008).
35. Sconce, E.A., Daly, A.K., Khan, T.I., Wynne, H.A. & Kamali, F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet. Genomics 16, 609-611 (2006).
36. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
37. Allabi, A.C., Gala, J.L., Desager, J.P., Heusterspreute, M. & Horsmans, Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol. 56, 653-657 (2003).
38. Schaid, D.J., Rowland, C.M., Tines, D.E., Jacobson, R.M. & Poland, G.A. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet. 70, 425-434 (2002).